Herceptin ®
Actief bestanddeel: Trastuzumab
Therapeutisch domein: Oncologie
Herceptin is een recombinant monoklonaal antilichaam dat gebruikt wordt bij bepaalde vormen van borstkanker.
Wetenschappelijke bijsluiter Herceptin (Trastuzumab)
Meer informatie over Herceptin?
If a pregnancy occurs while using Herceptin or within 7 months following the last dose of Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at +32 2 525 82 99. Additional information will be requested during a Herceptin-exposed pregnancy and the first year of the infant’s life. This will enable Roche to better understand the safety of Herceptin and to provide appropriate information to health authorities, healthcare providers and patients.
